Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Point mutations in the 23S ribosomal RNA gene have been associated with Helicobacter pylori clarithromycin resistance. This study aimed to detect the prevalence of these point mutations and to investigate the role of different point mutations in the success of eradication therapy. Methods: We retrospectively investigated a total of 464 consecutive patients who underwent an endoscopic examination and dual-priming oligonucleotide-based multiplex polymerase chain reaction for H. pylori between June 2014 and October 2019. For 289 patients with negative point mutations, standard triple therapy was used in 287 patients, and the bismuth-quadruple regimen was used in two patients. For 175 patients with positive point mutations (A2142G, A2143G, and both mutations), standard triple and bismuth-quadruple therapies were used in 37 patients and 138 patients, respectively. Results: The eradication rates of standard triple and bismuth-quadruple therapies showed no significant difference in mutation-negative patients or those with the A2142G point mutation. However, the eradication rate with bismuth-quadruple therapy was significantly higher than that with standard triple therapy in the group with the A2143G mutation or with the double mutation. The eradication rates for standard triple and bismuth-quadruple therapies, respectively, were 25.8% and 92.1% in the per-protocol group (p<0.001) and 24.2% and 85.2% in the intention-totreat analysis (p<0.001). Conclusions: The A2143G point mutation is the most prevalent cause of clarithromycin resistance. Bismuth-quadruple therapy is superior to standard triple therapy in patients with the A2143G or double point mutation.
Abstract
Background/Aims: Point mutations in the 23S ribosomal RNA gene have been associated with Helicobacter pylori clarithromycin resistance. This study aimed to detect the prevalence of these point mutations and to investigate the role of different point mutations in the success of eradication therapy. Methods: We retrospectively investigated a total of 464 consecutive patients who underwent an endoscopic examination and dual-priming oligonucleotide-based multiplex polymerase chain reaction for H. pylori between June 2014 and October 2019. For 289 patients with negative point mutations, standard triple therapy was used in 287 patients, and the bismuth-quadruple regimen was used in two patients. For 175 patients with positive point mutations (A2142G, A2143G, and both mutations), standard triple and bismuth-quadruple therapies were used in 37 patients and 138 patients, respectively. Results: The eradication rates of standard triple and bismuth-quadruple therapies showed no significant difference in mutation-negative patients or those with the A2142G point mutation. However, the eradication rate with bismuth-quadruple therapy was significantly higher than that with standard triple therapy in the group with the A2143G mutation or with the double mutation. The eradication rates for standard triple and bismuth-quadruple therapies, respectively, were 25.8% and 92.1% in the per-protocol group (p<0.001) and 24.2% and 85.2% in the intention-totreat analysis (p<0.001). Conclusions: The A2143G point mutation is the most prevalent cause of clarithromycin resistance. Bismuth-quadruple therapy is superior to standard triple therapy in patients with the A2143G or double point mutation.
참고문헌 (39)
- Fallone CA, "Helicobacter pylori Infection", N Engl J Med, 381, pp.588~ (2019)
- Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
- Fallone CA, "The Toronto consensus for the treatment of Helicobacter pylori infection in adults", Gastroenterology, 151, pp.51~69 (2016)
- Chey WD, "ACG clinical guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
- Thung I, "Review article : the global emergence of Helicobacter pylori antibiotic resistance", Aliment Pharmacol Ther, 43, pp.514~533 (2016)
- Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance", Gut, 59, pp.1143~1153 (2010)
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
- 김성은, "Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy", The Korean Journal of Internal Medicine, 30(6), pp.801~807 (2015), 대한내과학회[DOI]
- 김범진, "Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis", Journal of Korean Medical Science, 31(8), pp.1246~1253 (2016), 대한의학회
- Kato M, "Guidelines for the management of Helicobacter pylori infection in Japan : 2016 Revised Edition", Helicobacter, 24, pp.e12597~ (2019)
- Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Woo HY, "Dual-priming oligonucleotide-based multiplex PCR for the detection of Helicobacter pylori and determination of clarithromycin resistance with gastric biopsy specimens", Helicobacter, 14, pp.22~28 (2009)
- Lehours P, "DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin", BMC Gastroenterol, 11, pp.112~ (2011)
- Smith SM, "Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance", World J Gastroenterol, 20, pp.9912~9921 (2014)
- Pohl D, "Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing", World J Gastroenterol, 25, pp.4629~4660 (2019)
- 윤규현, "Clarithromycin-Based Standard Triple Therapy Can Still Be Effective for Helicobacter pylori Eradication in Some Parts of the Korea", Journal of Korean Medical Science, 29(9), pp.1240~1246 (2014), 대한의학회
- Yamade M, "Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan", J Gastroenterol Hepatol, 26, pp.1457~1461 (2011)
- Chung WC, "Dual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection", World J Gastroenterol, 20, pp.6547~6553 (2014)
- Agudo S, "Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reactionrestriction fragment length polymorphism", Rev Esp Quimioter, 24, pp.32~36 (2011)
- Mégraud F, "Helicobacter pylori detection and antimicrobial susceptibility testing", Clin Microbiol Rev, 20, pp.280~322 (2007)
- Cambau E, "Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori", J Clin Microbiol, 47, pp.3600~3607 (2009)
- Gerrits MM, "Helicobacter pylori and antimicrobial resistance : molecular mechanisms and clinical implications", Lancet Infect Dis, 6, pp.699~709 (2006)
- Francavilla R, "Clarithromycin-resistant genotypes and eradication of Helicobacter pylori", J Pediatr, 157, pp.228~232 (2010)
- Versalovic J, "Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori", Antimicrob Agents Chemother, 40, pp.477~480 (1996)
- Mégraud F, "H pylori antibiotic resistance : prevalence, importance, and advances in testing", Gut, 53, pp.1374~1384 (2004)
- Boyanova L, "Clarithromycin resistance mutations in Helicobacter pylori in association with virulence factors and antibiotic susceptibility of the strains", Microb Drug Resist, 22, pp.227~232 (2016)
- De Francesco V, "Clarithromycinresistant genotypes and eradication of Helicobacter pylori", Ann Intern Med, 144, pp.94~100 (2006)
- Park CS, "Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance", Am J Gastroenterol, 109, pp.1595~1602 (2014)
- Choi YI, "Tailored eradication vs empirical bismuth-containing quadruple therapy for firstline Helicobacter pylori eradication : a comparative, open trial", World J Gastroenterol, 25, pp.6743~6751 (2019)
- Ko SW, "Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy : systemic review and meta-analysis", Helicobacter, 24, pp.e12565~ (2019)
- Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012", Helicobacter, 18, pp.206~214 (2013)
- 장영운, "Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis", The Korean Journal of Internal Medicine, 34(5), pp.1022~1029 (2019), 대한내과학회[DOI]
- Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance", J Infect Dis, 208, pp.1123~1130 (2013)
- Owen RJ, "Molecular testing for antibiotic resistance in Helicobacter pylori", Gut, 50, pp.285~289 (2002)
- Stone GG, "A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori", Antimicrob Agents Chemother, 41, pp.712~714 (1997)
- Šterbenc A, "Helicobacter pylori virulence genes", World J Gastroenterol, 25, pp.4870~4884 (2019)
- Cho JH, "Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients", J Gastroenterol Hepatol, 34, pp.700~706 (2019)
- Bilal R, "Accuracy of noninvasive 13C-urea breath test compared to invasive tests for Helicobacter pylori detection", J Coll Physicians Surg Pak, 17, pp.84~88 (2007)
- Blaser MJ, "Heterogeneity of Helicobacter pylori", Eur J Gastroenterol Hepatol, 9(Suppl 1), pp.S3~S6 (2012)